BioNTech (BNTX) CEO Sahin Ugur Sells 86,000 Shares

What Happened

• Sahin Ugur, CEO of BioNTech SE, sold a total of 86,000 ordinary shares in two open-market transactions: 45,000 shares on 2026-09-11 at $96.93 each ($4,362,021) and 41,000 shares on 2026-09-14 at $99.45 each ($4,077,315). Total proceeds were approximately $8,439,336. These were sales (not purchases); sales are often routine and do not necessarily signal a change in company outlook.

Key Details

• Transaction dates & prices:
  • 2026-09-11: Sold 45,000 shares at $96.93 — $4,362,021
  • 2026-09-14: Sold 41,000 shares at $99.45 — $4,077,315
• Total shares sold: 86,000; total proceeds: ~$8.44 million.
• Shares owned after transaction: Not specified in the materials provided.
• Footnote: The shares are held by Medine GmbH; Sahin Ugur is the sole shareholder of Medine. 106,721 shares noted are held for a beneficiary under a trust where Medine exercises voting but not dispositive power. The reporting person may be deemed to beneficially own the shares held by Medine GmbH.
• Plan/filing timing: The Form 4 states the sales were effected under a Rule 10b5-1 trading plan established June 3, 2026. The Form 4 was filed on 2026-09-14 and appears timely relative to the reported trade dates.

Context

• Trades under a 10b5-1 plan are prearranged and can reduce inference that the insider traded on material non-public information; they are commonly used to sell shares on a set schedule. For retail investors, purchases typically carry more direct informational weight than routine sales, but these disclosures are useful to track insider liquidity and ownership structure.